A novel thyroid hormone receptor beta-selective agonist oral drug (THR-β agonist) developed by Madrigal Pharmaceuticals was designed to treat NASH patients [12]. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.